Cumberland Pharmaceuticals (NASDAQ:CPIX) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIXGet Rating) in a research note issued to investors on Friday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, TheStreet downgraded Cumberland Pharmaceuticals from a “c-” rating to a “d+” rating in a research note on Tuesday, February 22nd.

NASDAQ CPIX opened at $2.23 on Friday. The stock’s 50 day moving average is $2.66 and its 200 day moving average is $3.29. The company has a current ratio of 2.37, a quick ratio of 1.93 and a debt-to-equity ratio of 0.35. Cumberland Pharmaceuticals has a 12 month low of $2.17 and a 12 month high of $7.51. The stock has a market cap of $33.09 million, a PE ratio of -9.29 and a beta of 0.31.

Cumberland Pharmaceuticals (NASDAQ:CPIXGet Rating) last posted its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported $0.02 EPS for the quarter. Cumberland Pharmaceuticals had a negative return on equity of 4.21% and a negative net margin of 9.75%. The company had revenue of $11.18 million for the quarter.

Large investors have recently added to or reduced their stakes in the business. Morgan Stanley grew its position in Cumberland Pharmaceuticals by 131.3% in the 1st quarter. Morgan Stanley now owns 11,160 shares of the specialty pharmaceutical company’s stock valued at $34,000 after acquiring an additional 6,335 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Cumberland Pharmaceuticals in the 3rd quarter worth $32,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Cumberland Pharmaceuticals in the 4th quarter worth $94,000. State Street Corp purchased a new stake in shares of Cumberland Pharmaceuticals during the 4th quarter worth $307,000. Finally, Marshall Wace LLP purchased a new stake in shares of Cumberland Pharmaceuticals during the 4th quarter worth $373,000. 19.11% of the stock is currently owned by institutional investors and hedge funds.

About Cumberland Pharmaceuticals (Get Rating)

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

Read More

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.